Mainz, October 2015 – TRON Seminar in Translational Oncology
“RNA Therapeutics : New Era in Personalized Medicine?”, Prof. Dan Peer, PhD
Department of Cell Research and Immunology, Tel Aviv University (TAU), Israel
5 PM, Lecture Hall Building 708, University Medical Center Mainz
Langenbeckstr. 1, 55131 Mainz, Germany
Prof. Peer’s research interest is the selective targeting and reprogramming of cells using fully degradable nanomedicines. His lab is studying how to manipulate cells’ functions in order to generate novel strategies to treat inflammatory diseases and cancers and his work was among the first to demonstrate systemic delivery of RNA molecules using targeted nanocarriers to the immune system. He pioneered the use of RNA interference (RNAi) for in vivo validation of new drug targets within the immune system.
His current interests include the generation of novel platforms for delivery of therapeutics and imaging payloads into specific cell types and the utilization of these nanocarriers also for in vivo discovery and validation of new drug targets in leukocytes implicated diseases. Prof. Peer`s lab combines multidisciplinary approaches including immunology, cell and molecular biology, genetics, protein engineering, material sciences, nanotechnology and computational techniques for drug discovery and potentially for therapeutics. In addition, his group is developing nanomedicines by designing highly selective targeting moieties and novel nanocarriers, with an ultimate goal to translate some of the findings into clinical settings.
Prof. Dan Peer is an associate professor that leads an NIH-funded lab in the Faculty of Life Science and the Faculty of Engineering at Tel Aviv University (TAU). He is also the director of the Focal Technology Area consortium on Nanomedice for Personalized Theranostics, a national nanotechnology initiative supported also by the Leona M. and Harry B. Helmsley Nanotechnology Research Fund. Prof. Peer did his training at Tel Aviv University (B.Sc., M.Sc. and Ph.D.) with two internships (Cesar Milstein lab at Cambridge University UK and Robert Langer Lab at MIT). He then moved to Harvard Medical School for a postdoctoral training. He was recruited back to Tel Aviv University from Harvard University in 2008 to establish the Laboratory of NanoMedicine at Tel Aviv University.
Please find additional information about the visitor and his lab at: http://www6.tau.ac.il/danpeer/
Information about his publications can be found at: http://www.ncbi.nlm.nih.gov/pubmed?term=dan+peer&cmd=DetailsSearch